Drugs / HLX97
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07480681 | Mar 2026 → Mar 2028 expected | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX97 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07480681 ↗ |
| Action | Inhibit | “HLX97 (KAT6A/B Small Molecule Inhibitor)” NCT07480681 ↗ |
| Modality | Small molecule | “HLX97 (KAT6A/B Small Molecule Inhibitor)” NCT07480681 ↗ |
| Route | Oral | “HLX 97 will be taken as an oral medication.” NCT07480681 ↗ |
| Target | KAT6A | “HLX97 (KAT6A/B Small Molecule Inhibitor)” NCT07480681 ↗ |